Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to extraction of data according to the protocol)~* Male or female patients at least 18 years of age at time of informed consent~* Diagnosis of T2DM (type 2 diabetes mellitus)~* Xultophy® initiation prescribed at least 6 months before inclusion in this study (i.e., date of signed informed consent). Patients may or may not be continuing Xultophy® at study inclusion~* Minimum available data:a.) At the time of Xultophy® prescription: HbA1c value (or if unavailable, the most recent HbA1c value within 6 months before the first Xultophy® prescription);b.) At 6 months plus/minus 45 days after first Xultophy® prescription: HbA1c value~Exclusion Criteria:~* Type 1 diabetes~* Previous participation in this study. Participation is defined as having provided informed consent~* Participation in a clinical trial within 6 months before or 12 months after the first Xultophy® prescription (Participation in a non-interventional study is not an exclusion criteria)~* Mental incapacity, unwillingness or inability to provide informed consent, or language barriers precluding adequate understanding or co-operation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).